Xeris Biopharma Holdings, Inc. (XERS)
Market Cap | 806.94M |
Revenue (ttm) | 222.55M |
Net Income (ttm) | -45.08M |
Shares Out | 156.38M |
EPS (ttm) | -0.30 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 5,209,545 |
Open | 4.48 |
Previous Close | 4.48 |
Day's Range | 4.44 - 5.27 |
52-Week Range | 1.72 - 6.07 |
Beta | 0.91 |
Analysts | Strong Buy |
Price Target | 6.10 (+18.22%) |
Earnings Date | May 8, 2025 |
About XERS
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adul... [Read more]
Financial Performance
In 2024, Xeris Biopharma Holdings's revenue was $203.07 million, an increase of 23.89% compared to the previous year's $163.91 million. Losses were -$54.84 million, -11.92% less than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $6.1, which is an increase of 18.22% from the latest price.
News

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve Pie...

Xeris Biopharma Reports Record First Quarter 2025 Financial Results
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings
Xeris Biopharma Holdings, Inc. has shown consistent double-digit growth and is expected to continue this trend, with Q1 earnings projected to drive the share price higher. Key metrics to watch include...

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025.

Xeris Announces Changes to Its Board of Directors
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative p...

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Allison Wey - SVP of IR, Corporate Communications John Shannon - CEO Steve ...

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

Xeris to Participate in Upcoming Investor Conferences
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON,...

Xeris Expects to Exceed Full-Year 2024 Financial Guidance
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announce...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Of...

Xeris Biopharma Reports Third Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative inj...

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 4th - 10th, aiming to inspire discussion and provide investment ideas. WW International's pivot to GLP-1 medications raises co...

Xeris Biopharma: Time For A Reassessment
Xeris Biopharma is trading above my Buy Threshold of $2.76 and is nearing a potential breakout above the $3.25 resistance level. The company shows strong revenue growth, driven by products like Gvoke ...

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:03 AM ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants John Shannon - CEO Steven ...

Xeris Biopharma Reports Second Quarter 2024 Financial Results
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

Xeris Biopharma Announces CEO Succession Plan
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...